A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
- DOI
- 10.1016/j.medj.2023.07.006
- Published
- 2023-10
- Container
- Med
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.medj.2023.07.006,
title = {A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials},
author = {Alberto Hernando-Calvo and Maria Vila-Casadesús and Yacine Bareche and Alberto Gonzalez-Medina and Farnoosh Abbas-Aghababazadeh and Deborah Lo Giacco and Agatha Martin and Omar Saavedra and Irene Brana and Maria Vieito and Roberta Fasani and John Stagg and Francesco Mancuso and Benjamin Haibe-Kains and Ming Han and Roger Berche and Trevor J. Pugh and Oriol Mirallas and Jose Jimenez and Nadia Saoudi Gonzalez and Claudia Valverde and Eva Muñoz-Couselo and Cristina Suarez and Marc Diez and Elena Élez and Jaume Capdevila and Ana Oaknin and Cristina Saura and Teresa Macarulla and Joan Carles Galceran and Enriqueta Felip and Rodrigo Dienstmann and Philippe L. Bedard and Paolo Nuciforo and Joan Seoane and Josep Tabernero and Elena Garralda and Ana Vivancos},
year = {2023},
journal = {Med},
doi = {10.1016/j.medj.2023.07.006},
url = {https://doi.org/10.1016/j.medj.2023.07.006}
}RIS
TY - JOUR TI - A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials AU - Alberto Hernando-Calvo AU - Maria Vila-Casadesús AU - Yacine Bareche AU - Alberto Gonzalez-Medina AU - Farnoosh Abbas-Aghababazadeh AU - Deborah Lo Giacco AU - Agatha Martin AU - Omar Saavedra AU - Irene Brana AU - Maria Vieito AU - Roberta Fasani AU - John Stagg AU - Francesco Mancuso AU - Benjamin Haibe-Kains AU - Ming Han AU - Roger Berche AU - Trevor J. Pugh AU - Oriol Mirallas AU - Jose Jimenez AU - Nadia Saoudi Gonzalez AU - Claudia Valverde AU - Eva Muñoz-Couselo AU - Cristina Suarez AU - Marc Diez AU - Elena Élez AU - Jaume Capdevila AU - Ana Oaknin AU - Cristina Saura AU - Teresa Macarulla AU - Joan Carles Galceran AU - Enriqueta Felip AU - Rodrigo Dienstmann AU - Philippe L. Bedard AU - Paolo Nuciforo AU - Joan Seoane AU - Josep Tabernero AU - Elena Garralda AU - Ana Vivancos PY - 2023 JO - Med DO - 10.1016/j.medj.2023.07.006 UR - https://doi.org/10.1016/j.medj.2023.07.006 ER -
APA
Hernando-Calvo, A., Vila-Casadesús, M., Bareche, Y., Gonzalez-Medina, A., Abbas-Aghababazadeh, F., Giacco, D. L., Martin, A., Saavedra, O., Brana, I., Vieito, M., Fasani, R., Stagg, J., Mancuso, F., Haibe-Kains, B., Han, M., Berche, R., Pugh, T. J., Mirallas, O., Jimenez, J., Gonzalez, N. S., Valverde, C., Muñoz-Couselo, E., Suarez, C., Diez, M., Élez, E., Capdevila, J., Oaknin, A., Saura, C., Macarulla, T., Galceran, J. C., Felip, E., Dienstmann, R., Bedard, P. L., Nuciforo, P., Seoane, J., Tabernero, J., Garralda, E., & Vivancos, A. (2023). A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. https://doi.org/10.1016/j.medj.2023.07.006
Source records
- crossref · retrieved 2026-09-26T14:11:40.931Z